Literature DB >> 18040100

What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies.

Athula Sumathipala1.   

Abstract

OBJECTIVE: To review published literature for the highest level of evidence on the efficacy of treatment for patients with medically unexplained symptoms.
METHODS: A comprehensive literature search was carried out in Cochrane library, Medline (1971-2007), PsychINFO (1974-2006), and EMBASE (1980-2007) to identify pharmacological, nonpharmacological, psychological, and other interventions, using the search terms "medically unexplained symptoms," "somatisation," "somatization," "somatoform disorders," "psychological therapies," "cognitive behavior therapy," "pharmacological therapies," "management," "therapy," "drug therapy," and "anti-depressants" with Boolean operators AND and OR on the entire text. Searches were confined to literature in English.
RESULTS: Studies were carried out in primary, secondary, and tertiary care settings. The therapists ranged from medical specialists, psychiatrists, and psychologists to primary care physicians. Three types of interventions (antidepressant medication, cognitive behavioral therapy (CBT), and other nonspecific interventions) were supported by evidence on the efficacy of treatment for patients with medically unexplained symptoms. There is more level I evidence for CBT compared with the amount for other approaches. There was only one study reported from the developing world.
CONCLUSIONS: CBT is efficacious for either symptom syndromes or for the broader category of medically unexplained symptoms, reducing physical symptoms, psychological distress, and disability. A relatively small number of studies were carried out in primary care, but the trend has been changing over the last decade. No studies have compared pharmacological and psychological treatments. Most trials assessed only short-term outcomes. Use of divergent selection procedures, interventions, outcome measures, and instruments, and other methodological differences observed in these studies hamper the ability to compare treatment effects across studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040100     DOI: 10.1097/PSY.0b013e31815b5cf6

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  30 in total

1.  [Somatoform disorders and functional somatic syndromes].

Authors:  C Lahmann; P Henningsen; A Dinkel
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

2.  Fear of medical illness: differential diagnosis, workup, and treatment.

Authors:  Janet C Kennedy; Jeff C Huffman; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  Conversion disorder: advances in our understanding.

Authors:  Anthony Feinstein
Journal:  CMAJ       Date:  2011-04-18       Impact factor: 8.262

Review 4.  Association of somatoform disorders with anxiety and depression in women in low and middle income countries: a systematic review.

Authors:  Rahul Shidhaye; Emily Mendenhall; Kethakie Sumathipala; Athula Sumathipala; Vikram Patel
Journal:  Int Rev Psychiatry       Date:  2013-02

5.  A randomized trial of treatments for high-utilizing somatizing patients.

Authors:  Arthur J Barsky; David K Ahern; Mark R Bauer; Nyryan Nolido; E John Orav
Journal:  J Gen Intern Med       Date:  2013-03-14       Impact factor: 5.128

6.  Non-specific, functional, and somatoform bodily complaints.

Authors:  Rainer Schaefert; Constanze Hausteiner-Wiehle; Winfried Häuser; Joram Ronel; Markus Herrmann; Peter Henningsen
Journal:  Dtsch Arztebl Int       Date:  2012-11-23       Impact factor: 5.594

7.  The contribution of high levels of somatic symptom severity to sickness absence duration, disability and discharge.

Authors:  Rob Hoedeman; Annette H Blankenstein; Boudien Krol; Petra C Koopmans; Johan W Groothoff
Journal:  J Occup Rehabil       Date:  2010-06

8.  The effectiveness of a training for patients with unexplained physical symptoms: protocol of a cognitive behavioral group training and randomized controlled trial.

Authors:  Lyonne N L Zonneveld; Adriaan van 't Spijker; Jan Passchier; Jan J van Busschbach; Hugo J Duivenvoorden
Journal:  BMC Public Health       Date:  2009-07-20       Impact factor: 3.295

9.  Severe MUPS in a sick-listed population: a cross-sectional study on prevalence, recognition, psychiatric co-morbidity and impairment.

Authors:  Rob Hoedeman; Boudien Krol; Nettie Blankenstein; Petra C Koopmans; Johan W Groothoff
Journal:  BMC Public Health       Date:  2009-12-01       Impact factor: 3.295

10.  Cognitive-behavioural therapy v. structured care for medically unexplained symptoms: randomised controlled trial.

Authors:  A Sumathipala; S Siribaddana; M R N Abeysingha; P De Silva; M Dewey; M Prince; A H Mann
Journal:  Br J Psychiatry       Date:  2008-07       Impact factor: 9.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.